BioCryst reported third quarter 2026 results that exceeded top and bottom-line expectations, characterized by robust ORLADEYO demand and an improved expense outlook. Total revenue of $180.3 million was bolstered by the transition to a sole-source specialty pharmacy model, while net income grew to $37.9 million from $12.9 million in the prior-year period.
Key Highlights
- ORLADEYO net revenue reached $174.8 million, beating the $164.2 million estimate, though growth was partially aided by a stable inventory build during the CareMed transition.
- Management raised full year 2026 total revenue guidance to a range of $715 million to $730 million, up from the previous $690 million to $715 million range.
- Non-GAAP operating expense guidance improved to $415–$425 million, reflecting $30–$35 million in anticipated annual savings from the Birmingham site closure.